Navigation Links
Everist Genomics Announces Worldwide Availability of OncoDefender™-CRC
Date:3/28/2011

ANN ARBOR, Mich., March 28, 2011 /PRNewswire/ -- Everist Genomics today announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor.  The OncoDefender-CRC test examines expression levels of a panel of genes extracted from formalin-fixed paraffin-embedded cancer tissue taken at the time of surgery, and uses a proprietary computer-generated decision rule to identify patients who are at risk of recurrence.  Patients identified by OncoDefender-CRC at high-risk of cancer recurrence may benefit from adjuvant therapy or other more aggressive treatment options, as reported at the 2011 American Society of Clinical Oncology (ASCO) meeting. (1)

(Logo: https://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

"We are pleased to deliver a new molecular prognostic test capable of assessing recurrence risk in early stage colorectal cancer patients, including the neglected stage I subset, where the lack of positive predictive prognostics presents a significant unmet need," said Prasad Sunkara, Ph.D., Chief Executive Officer of Everist Genomics.  OncoDefender-CRC was developed through extensive clinical research and assay validation studies involving over 500 patients from around the world.  "OncoDefender-CRC will help physicians make patient management decisions that promptly and reliably direct the most effective treatment to those individual Stage I/II colon cancer and Stage I rectal cancer patients at high risk for tumor recurrence, while minimizing the exposure of low-risk patients to unnecessary, costly, and potentially toxic chemotherapy and/or radiotherapy."

Traditional standards for assessing a patient's risk of cancer recurrence have depended solely on the cancer's a
'/>"/>

SOURCE Everist Genomics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genetics Squared Changes Name To Everist Genomics
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
6. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
10. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
11. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... KENNEWICK, Wash. , Dec. 23, 2014 /PRNewswire/ ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that it has ... the Food and Drug Administration ("FDA") for marketing ... to Section 513(f)(2) of the U.S. Food, Drug ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... 2011 ArjoHuntleigh, Inc. is pleased to announce ... Compression Devices with HealthTrust Purchasing Group, L.P. (HealthTrust). ... members to take advantage of special pricing and ... (IPC) devices for the prevention of deep vein ...
... Ltd, a leading source for life science sector analysis and ... sales, revealed today that Sanofi is expected to take the ... hold it through 2016. The French drug maker has raced ... activity, with the $20bn purchase this year of US biotechnology ...
Cached Medicine Technology:ArjoHuntleigh Awarded Vascular Compression Contract With HealthTrust Purchasing Group 2Sanofi Tops Pfizer as Number One for Global Pharma Sales 2
(Date:12/26/2014)... AZ (PRWEB) December 26, 2014 ... source for the best in heating, cooling and ... for 24 hour emergency services in 2014 with ... alike know that Arizona is known for its ... company that understands the intricacies and details of ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... HOLX ) today announced that Patrick Sullivan, Executive ... at the Lehman,Brothers Eleventh Annual Global Healthcare Conference being ... Miami, Florida., Interested parties are invited to listen ... Thursday, March 20, at 10:15 a.m.,Eastern Time on the ...
... German . , Scientists at the ... of haemo-globin. Haemoglobin transports oxygen in the red blood ... new haemoglobin type appears optically to be transporting little ... a similar picture to patients suffering from an inherited ...
... ENGLEWOOD, Colo., March 17 Baxa Corporation ... Training, Academics and Resources),Center course offerings. Safe ... developed for nurses, pharmacists and physicians that ... course combines hands-on,experience with regulatory compliance and ...
... to new drugs to check vascular proliferation that is ... (HealthDay News) -- Researchers have pinpointed a biological pathway ... behind most cases of blindness in the United States. ... suggests a new therapeutic target for such ophthalmic diseases ...
... CARMEL, Ind., March 17 Conseco, Inc. (NYSE:,CNO) today ... Partners II,L.P. to nominate two of its representatives to ... been reviewing strategic,alternatives and has engaged the investment banking ... CEO Jim Prieur said, "We share with Steel Partners, ...
... Inc.,(Nasdaq: ANSS ), a global innovator of ... processes, today announced it is a,sponsor of the ... Museum of,Natural History in Pittsburgh. This is the ... accurate, immersive environments that are,composed of original fossil ...
Cached Medicine News:Health News:Hologic to Present at Lehman Brothers Healthcare Conference 2Health News:Bonn scientists discover new hemoglobin type 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 3Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 2Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: